


Claims

1. A compound of Formula (I)



or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein

R^1 is H, LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂,

$R^2, R^{2'}$ are independently H, Hal, OH, CN, LA, O(LA),

R^3 is H, LA, Hal, OH, SH, S(LA), CN, NO₂, NH₂, O(LA), (LA)OCO(LA), (LA)COO(LA), NH(LA), NHCOO(LA), N(LA)₂, (LA)NH₂, (LA)NH(LA), SO₂NH₂, SO₂(LA), or L-Cyc²,

R^4 is H, LA, (LA)OH, (LA)NH(R²), O(LA), Cyc³,

R^5 is H, LA,

R^4, R^5 together with the atoms they are attached to, can form a 4, 5, 6 or 7 membered heterocycle, having 1 or 2 heteroatoms, which is optionally substituted by R⁶,

R^6 is H, LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂,

W is -NR⁶COR⁴ or -CON(R⁴)(R⁵),

X is N or CH,

Y is O or CH₂,

Z is NH, N(LA), S, CH₂, CH(LA), C(LA)₂,

Cyc¹ is a mono- or binuclear, aliphatic or aromatic, 4, 5, 6, 7, 8, 9 or 10 membered homo- or heterocycle, having 0, 1, 2, 3 or 4 N, O and/or S atoms, which may be substituted by one or two oxo groups, and in which one N atom may be replaced by a N⁺-O⁻ group,

Cyc² is a mono- or binuclear, aliphatic or aromatic, 4, 5, 6, 7, 8, 9 or 10 membered homo- or heterocycle, having 0, 1, 2, 3 or 4 N, O and/or S atoms, which may be mono-substituted by an oxo group, S(LA), SO₂(LA), N₃, NHCOH, NHCO(LA), NHCOO(LA), NHSO₂(LA),

- COO(LA), CONH₂, (LA)CONH₂, CONH(LA), L-Cyc³ or A, or independently mono-, di-, tri- or tetra-substituted by LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂, CO(LA), and in which one N atom may be replaced by a N⁺-O⁻ group,
- 5 Cyc³ is a monocyclic, aliphatic or aromatic homo- or heterocycle having 0, 1, 2 or 3 N, N⁺-O⁻, O and/or S atoms and 5 or 6 skeleton atoms, which may be mono- or di-substituted by LA, Hal, OH, CN, NO₂, NH₂, O(LA), S(LA), NH(LA), N(LA)₂, and in which one N atom may be replaced by a N⁺-O⁻ group,
- 10 L is a bond, or a unbranched alkyl or alkenyl linker, having 1, 2 or 3 carbon atoms, in which one CH₂ group may be replaced by a carbonyl group,
- LA is unbranched or branched alkyl, alkenyl or alkynyl, having 1, 2, 3, 4 or 5 carbon atoms, wherein one, two or three H atoms may be replaced by Hal,
- 15 A is a unbranched or branched alkyl or alkenyl chain having up to 25 non-hydrogen atoms, wherein 1, 2, 3, 4, 5 or 6 CH₂ groups may be replaced by O, S, NH, CO, N(LA), SO₂, and 1-7 H atoms may be replaced by Hal, and one CH₃ group may be replaced by OH, NH₂ or Cyc¹,
- 20 Hal is F, Cl, Br or I.

2. The compound according to Claim 1, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, in which the residues not designated in greater detail have the meaning indicated for Formula (I), but in which

25

- in Subformula 1
- 30 Z is H, NCH₃, CH₂,
- in Subformula 2
- W is -NR⁵COR⁴,
- in Subformula 3
- 35 W is -CON(R⁴)(R⁵),

in Subformula 4

Y is O,

5 in Subformula 5

Z is H, NCH₃, CH₂,
R⁴, R⁵ are methyl,

in Subformula 6

10 W is -NR⁵COR⁴,
R⁴, R⁵ together with the atoms they are attached to, form piperidin-2-one
or pyrrolidin-2-one,
R⁶ is H,

15 in Subformula 7

W is -CON(R⁴)(R⁵),
R⁴ is methyl,
R⁵ is H,

20 in Subformula 8

X is N,

in Subformula 9

25 W is -NR⁵COR⁴,
R⁴ is methyl, hydroxymethyl, tert-butyloxy, neopentyl,
R⁵ is H, methyl, ethyl, isopropyl, fluoromethyl,

in Subformula 10

30 W is -NR⁵COR⁴,
R⁴, R⁵ are methyl,

in Subformula 11

35 X is N,
R¹ is H,

- in Subformula 12
Cyc¹ is indanyl, indolyl, isoquinoliny, benzoisoxazolyl,
- in Subformula 13
5 Cyc¹ is phenyl, which is independently mono-, di- or tri-substituted by F, Br, CN, O(LA), LA,
- in Subformula 14
Cyc¹ is phenyl, which is substituted in 4-position by L-Cyc²,
- 10 in Subformula 15
Cyc¹ is phenyl, which is substituted in 4-position by L-Cyc², and in 1- and/or 2-position by F,
- in Subformula 16
15 X is N,
Y is O,
Z is H, NCH₃, CH₂,
- in Subformula 17
20 X is N,
Y is O,
Z is NCH₃, CH₂,
R¹ is H,
- 25 in Subformula 18
W is -NR⁵COR⁴,
X is N,
Y is O,
Z is NCH₃, CH₂,
30 R¹ is H,
Cyc¹ is phenyl, which is independently mono-, di- or tri-substituted by F, Br, CN, O(LA), LA,
- in Subformula 19
35 W is -NR⁵COR⁴,

	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
	R ¹	is H,
5	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
	in Subformula 20	
	W	is -NR ⁵ COR ⁴ ,
10	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
	R ¹	is H,
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
15		
	in Subformula 21	
	X	is N,
	Y	is O,
20	Z	is NCH ₃ , CH ₂ , S,
	R ⁴	is methyl,
	R ⁵	is methyl, ethyl, isopropyl,
	R ¹	is H,
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
25		
	Cyc ²	is pyridin-2, 3, or 4-yl, or pyrazin-2-yl, each of which is unsubstituted or substituted by HO(LA), LA, NH ₂ , CN,
	in Subformula 22	
30	W	is -NR ⁵ COR ⁴ ,
	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ , S,
	R ⁴ , R ⁵	together with the atoms they are attached to, form piperidin-2-one
35	R ¹	is H,

Cyc¹ is phenyl, which is substituted in 4-position by L-Cyc² and, optionally, in 1- and/or 2-position by F,

Cyc² is pyridin-2, 3, or 4-yl, or pyrazin-2-yl, each of which is unsubstituted or substituted by HO(LA), LA, NH₂, CN.

5

3. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

1-(2-{6-[4-(5-Methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylamino}-ethyl)-piperidin-2-one,

10

1-[2-(Methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-piperidin-2-one,

5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid {6-[4-{5-[4-(6-{[2-(acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-yl}-piperazin-1-yl)-6-oxo-hexyl]-amide,

15

6-[5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoic acid {5-[4-(6-{[2-(acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-ylmethyl}-methyl-amide,

N-[2-({6-[2-Fluoro-4-(5-fluoro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

20

N-[2-({6-[2-Fluoro-4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[2-Fluoro-4-(6-morpholin-4-yl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(2-Amino-pyrimidin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

25

N-[2-({6-[4-(2-Cyano-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(2-Fluoro-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(3-Cyano-pyridin-4-yl)-2-fluoro-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

30

N-[2-({6-[4-(3-Cyano-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(5-Amino-pyrazin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

- N-[2-({6-[4-(5-Azido-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(5-Fluoro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 5 N-[2-({6-[4-(5-Methoxy-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Acetylamino-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Acetylamino-pyridin-3-yl)-2-fluoro-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 10 N-[2-({6-[4-(6-Amino-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Cyano-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 15 N-[2-({6-[4-(6-Hydroxymethyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Methanesulfonyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-{5-[4-(6-{[2-(Acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-yl}-acetamide,
- 20 N-Ethyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- N-Isopropyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- 25 N-Methyl-3-(methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-propionamide,
- N-Methyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- N-Methyl-N-(2-{methyl-[6-(4-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- 30 N-Methyl-N-(2-{methyl-[6-(4-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- N-Methyl-N-(2-{methyl-[6-(4-thiazol-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(1H-pyrrolo[2,3-c]pyridin-5-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- 35 N-Methyl-N-[2-(methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

N-Methyl-N-[2-(methyl-{6-[4-(5-nitro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

N-Methyl-N-[2-(methyl-{6-[4-(6-methylaminomethyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

5 N-Methyl-N-[2-(methyl-{6-[4-(6-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

N-Methyl-N-[2-(methyl-{6-[4-(6-methyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

10 N-Methyl-N-[2-(methyl-{6-[4-(6-morpholin-4-yl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

N-Methyl-N-[2-(methyl-{6-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

N-Methyl-N-[2-(methyl-{6-[4-(6-(4-methyl-piperazin-1-yl)-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,

15 or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

4. A pharmaceutical composition comprising a compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of
20 each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

5. A compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including
25 mixtures thereof in all ratios, for use in the treatment of a hyperproliferative, inflammatory or degenerative disease.

6. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in
30 all ratios, wherein the hyperproliferative disease is cancer.

7. The compound for use according to Claim 6, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in
35 all ratios, wherein the cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head & neck, renal,

kidney, liver, ovarian, prostate, uterine, oesophageal, testicular, gynecological, thyroid cancer, melanoma, acute myelogenous leukemia, multiple myeloma, chronic myelogenous leukemia, myeloid cell leukemia, Kaposi's sarcoma.


- 5 8. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the inflammatory disease is selected from multiple sclerosis, rheumatoid arthritis, systemic lupus or inflammatory bowel disease.
- 10 9. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the degenerative disease is selected from osteoarthritis or Alzheimer's disease.
- 15 10. Use of a compound of one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of a hyperproliferative, inflammatory or degenerative disease.
- 20 11. Use according to claim 10 wherein the disease is cancer.
12. Use according to claim 11 wherein the cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head & neck, renal, kidney, liver, ovarian, prostate, uterine, oesophageal, testicular, gynecological, thyroid cancer, melanoma, acute myelogenous leukemia, multiple myeloma, chronic myelogenous leukemia, myeloid cell leukemia, Kaposi's sarcoma.
- 25 13. A method for treating a hyperproliferative, inflammatory or degenerative disease, comprising administering to a subject a compound of any of claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.
- 30 14. The method of claim 13, wherein the cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head & neck, renal, kidney, liver, ovarian, prostate, uterine, oesophageal, testicular,
- 35

gynecological, thyroid cancer, melanoma, acute myelogenous leukemia, multiple myeloma, chronic myelogenous leukemia, myeloid cell leukemia, Kaposi's sarcoma.


15. Set (kit) consisting of separate packs of

- 5 a) an effective amount of a compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and
b) an effective amount of a further medicament active ingredient.


- 10 16. Process for the manufacture of compounds of Formula (I), wherein a compound of Formula (V)



is reacted with a compound of Formula (IV)



15 to yield a compound of Formula (III)



which is then further reacted with a compound of Formula (II)




20 to yield a compound of Formula (I), wherein

LG¹, LG² are independently Hal.

Claims

1. A compound of Formula (I)



or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein

- R^1 is H, LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂,
 $R^{2'}, R^{2''}$ are independently H, Hal, OH, CN, LA, O(LA),
 R^3 is H, LA, Hal, OH, SH, S(LA), CN, NO₂, NH₂, O(LA), (LA)OCO(LA),
 (LA)COO(LA), NH(LA), NHCOO(LA), N(LA)₂, (LA)NH₂,
 (LA)NH(LA), SO₂NH₂, SO₂(LA),
 or L-Cyc²,
 R^4 is H, LA, (LA)OH, (LA)NH(R²), O(LA), Cyc³,
 R^5 is H, LA,
 R^4, R^5 together with the atoms they are attached to, can form a 4, 5, 6 or 7 membered heterocycle, having 1 or 2 heteroatoms, which is optionally substituted by R⁶,
 R^6 is H, LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂,
 W is -NR⁵COR⁴ or -CON(R⁴)(R⁵),
 X is N or CH,
 Y is O or CH₂,
 Z is NH, N(LA), S, CH₂, CH(LA), C(LA)₂,
 Cyc^1 is a mono- or binuclear, aliphatic or aromatic, 4, 5, 6, 7, 8, 9 or 10 membered homo- or heterocycle, having 0, 1, 2, 3 or 4 N, O and/or S atoms, which may be substituted by one or two oxo groups, and in which one N atom may be replaced by a N⁺-O⁻ group,
 Cyc^2 is a mono- or binuclear, aliphatic or aromatic, 4, 5, 6, 7, 8, 9 or 10 membered homo- or heterocycle, having 0, 1, 2, 3 or 4 N, O and/or S atoms, which may be mono-substituted by an oxo group, S(LA), SO₂(LA), N₃, NHCOH, NHCO(LA), NHCOO(LA), NHSO₂(LA),

- COO(LA), CONH₂, (LA)CONH₂, CONH(LA), L-Cyc³ or A, or independently mono-, di-, tri- or tetra-substituted by LA, Hal, OH, CN, NO₂, NH₂, O(LA), NH(LA), N(LA)₂, CO(LA), and in which one N atom may be replaced by a N⁺-O⁻ group,
- 5 Cyc³ is a monocyclic, aliphatic or aromatic homo- or heterocycle having 0, 1, 2 or 3 N, N⁺-O⁻, O and/or S atoms and 5 or 6 skeleton atoms, which may be mono- or di-substituted by LA, Hal, OH, CN, NO₂, NH₂, O(LA), S(LA), NH(LA), N(LA)₂, and in which one N atom may be replaced by a N⁺-O⁻ group,
- 10 L is a bond, or a unbranched alkyl or alkenyl linker, having 1, 2 or 3 carbon atoms, in which one CH₂ group may be replaced by a carbonyl group,
- LA is unbranched or branched alkyl, alkenyl or alkynyl, having 1, 2, 3, 4 or 5 carbon atoms, wherein one, two or three H atoms may be replaced by Hal,
- 15 A is a unbranched or branched alkyl or alkenyl chain having up to 25 non-hydrogen atoms, wherein 1, 2, 3, 4, 5 or 6 CH₂ groups may be replaced by O, S, NH, CO, N(LA), SO₂, and 1-7 H atoms may be replaced by Hal, and one CH₃ group may be replaced by OH, NH₂ or Cyc¹,
- 20 Hal is F, Cl, Br or I.

2. The compound according to Claim 1, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, in which the residues not designated in greater detail have the meaning indicated for Formula (I), but in which

25

- in Subformula 1
- 30 Z is H, NCH₃, CH₂,
- in Subformula 2
- W is -NR⁵COR⁴,
- in Subformula 3
- 35 W is -CON(R⁴)(R⁵),

	in Subformula 4	
	Y	is O,
5	in Subformula 5	
	Z	is H, NCH ₃ , CH ₂ ,
	R ⁴ , R ⁵	are methyl,
	in Subformula 6	
10	W	is -NR ⁵ COR ⁴ ,
	R ⁴ , R ⁵	together with the atoms they are attached to, form piperidin-2-one or pyrrolidin-2-one,
	R ⁶	is H,
15	in Subformula 7	
	W	is -CON(R ⁴)(R ⁵),
	R ⁴	is methyl,
	R ⁵	is H,
20	in Subformula 8	
	X	is N,
	in Subformula 9	
	W	is -NR ⁵ COR ⁴ ,
25	R ⁴	is methyl, hydroxymethyl, tert-butyloxy, neopentyl,
	R ⁵	is H, methyl, ethyl, isopropyl, fluoromethyl,
	in Subformula 10	
	W	is -NR ⁵ COR ⁴ ,
30	R ⁴ , R ⁵	are methyl,
	in Subformula 11	
	X	is N,
	R ¹	is H,
35		

	in Subformula 12	
	Cyc ¹	is indanyl, indolyl, isoquinoliny, benzoisoxazolyl,
	in Subformula 13	
5	Cyc ¹	is phenyl, which is independently mono-, di- or tri-substituted by F, Br, CN, O(LA), LA,
	in Subformula 14	
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² ,
10	in Subformula 15	
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² , and in 1- and/or 2-position by F,
	in Subformula 16	
15	X	is N,
	Y	is O,
	Z	is H, NCH ₃ , CH ₂ ,
	in Subformula 17	
20	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
	R ¹	is H,
25	in Subformula 18	
	W	is -NR ⁵ COR ⁴ ,
	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
30	R ¹	is H,
	Cyc ¹	is phenyl, which is independently mono-, di- or tri-substituted by F, Br, CN, O(LA), LA,
	in Subformula 19	
35	W	is -NR ⁵ COR ⁴ ,

	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
	R ¹	is H,
5	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
	in Subformula 20	
	W	is -NR ⁵ COR ⁴ ,
10	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ ,
	R ¹	is H,
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
15		
	in Subformula 21	
	X	is N,
	Y	is O,
20	Z	is NCH ₃ , CH ₂ , S,
	R ⁴	is methyl,
	R ⁵	is methyl, ethyl, isopropyl,
	R ¹	is H,
	Cyc ¹	is phenyl, which is substituted in 4-position by L-Cyc ² and, optionally, in 1- and/or 2-position by F,
25		
	Cyc ²	is pyridin-2, 3, or 4-yl, or pyrazin-2-yl, each of which is unsubstituted or substituted by HO(LA), LA, NH ₂ , CN,
	in Subformula 22	
30	W	is -NR ⁵ COR ⁴ ,
	X	is N,
	Y	is O,
	Z	is NCH ₃ , CH ₂ , S,
	R ⁴ , R ⁵	together with the atoms they are attached to, form piperidin-2-one
35	R ¹	is H,

Cyc¹ is phenyl, which is substituted in 4-position by L-Cyc² and, optionally, in 1- and/or 2-position by F,

Cyc² is pyridin-2, 3, or 4-yl, or pyrazin-2-yl, each of which is unsubstituted or substituted by HO(LA), LA, NH₂, CN.

5

3. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

1-(2-{6-[4-(5-Methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylamino}-ethyl)-piperidin-2-one,

10 one,
1-[2-(Methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-piperidin-2-

5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid [6-(4-{5-[4-(6-{[2-(acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-yl}-piperazin-1-yl)-6-oxo-hexyl]-amide,

15 6-[5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoic acid {5-[4-(6-{[2-(acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-ylmethyl}-methyl-amide,

N-[2-({6-[2-Fluoro-4-(5-fluoro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

20 N-[2-({6-[2-Fluoro-4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[2-Fluoro-4-(6-morpholin-4-yl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(2-Amino-pyrimidin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

25 N-[2-({6-[4-(2-Cyano-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(2-Fluoro-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

30 N-[2-({6-[4-(3-Cyano-pyridin-4-yl)-2-fluoro-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(3-Cyano-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

N-[2-({6-[4-(5-Amino-pyrazin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,

- N-[2-({6-[4-(5-Azido-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(5-Fluoro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 5 N-[2-({6-[4-(5-Methoxy-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Acetylamino-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Acetylamino-pyridin-3-yl)-2-fluoro-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 10 N-[2-({6-[4-(6-Amino-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Cyano-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- 15 N-[2-({6-[4-(6-Hydroxymethyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-[2-({6-[4-(6-Methanesulfonyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-methyl-amino)-ethyl]-N-methyl-acetamide,
- N-{5-[4-(6-{[2-(Acetyl-methyl-amino)-ethyl]-methyl-amino}-pyrazin-2-yloxy)-phenyl]-pyridin-2-yl}-acetamide,
- 20 N-Ethyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- N-Isopropyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- 25 N-Methyl-3-(methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-propionamide,
- N-Methyl-N-(2-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-ylsulfanyl}-ethyl)-acetamide,
- N-Methyl-N-(2-{methyl-[6-(4-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- 30 N-Methyl-N-(2-{methyl-[6-(4-pyridin-4-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- N-Methyl-N-(2-{methyl-[6-(4-thiazol-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl)-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(1H-pyrrolo[2,3-c]pyridin-5-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(5-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- 35

- N-Methyl-N-[2-(methyl-{6-[4-(5-nitro-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(6-methylaminomethyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- 5 N-Methyl-N-[2-(methyl-{6-[4-(6-methyl-pyridin-2-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(6-methyl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- N-Methyl-N-[2-(methyl-{6-[4-(6-morpholin-4-yl-pyridin-3-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- 10 N-Methyl-N-[2-(methyl-{6-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- N-Methyl-N-[2-[methyl-(6-{4-[6-(4-methyl-piperazin-1-yl)-pyridin-2-yl]-phenoxy]-pyrazin-2-yl}-amino)-ethyl]-acetamide,
- 15 or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.
4. A pharmaceutical composition comprising a compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient,
- 20 together with a pharmaceutically acceptable carrier.
5. A compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use in the treatment of a hyperproliferative, inflammatory or degenerative disease.
- 25
6. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the hyperproliferative disease is cancer.
- 30
7. The compound for use according to Claim 6, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head & neck, renal,
- 35

kidney, liver, ovarian, prostate, uterine, oesophageal, testicular, gynecological, thyroid cancer, melanoma, acute myelogenous leukemia, multiple myeloma, chronic myelogenous leukemia, myeloid cell leukemia, Kaposi's sarcoma.

5 8. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the inflammatory disease is selected from multiple sclerosis, rheumatoid arthritis, systemic lupus or inflammatory bowel disease.

10 9. The compound for use according to Claim 5, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the degenerative disease is selected from osteoarthritis or Alzheimer's disease.

15 10. Use of a compound of one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of a hyperproliferative, inflammatory or degenerative disease.

20 11. Use according to claim 10 wherein the disease is cancer.

12. Use according to claim 11 wherein the cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head & neck, renal, kidney, liver, ovarian, prostate, uterine, oesophageal, testicular,
25 gynecological, thyroid cancer, melanoma, acute myelogenous leukemia, multiple myeloma, chronic myelogenous leukemia, myeloid cell leukemia, Kaposi's sarcoma.


30

35


13. Set (kit) consisting of separate packs of

- 5 a) an effective amount of a compound according to one or more of Claims 1 to 3, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and
b) an effective amount of a further medicament active ingredient.


10 14. Process for the manufacture of compounds of Formula (I), wherein a compound of Formula (V)



is reacted with a compound of Formula (IV)



15 to yield a compound of Formula (III)



which is then further reacted with a compound of Formula (II)



to yield a compound of Formula (I), wherein
LG¹, LG² are independently Hal.